Literature DB >> 26865293

Costs of Care for Hospitalization for Pemphigus in the United States.

Derek Hsu1, Joaquin Brieva1, Jonathan I Silverberg2.   

Abstract

IMPORTANCE: Pemphigus is an autoimmune blistering disorder associated with significant morbidity and mortality. However, little is known about the inpatient burden of pemphigus.
OBJECTIVE: To determine the incidence of and risk factors for hospitalization with pemphigus and cost of care. DESIGN, SETTING, AND PARTICIPANTS: The 2002-2012 Nationwide Inpatient Sample provided by the Healthcare Cost and Utilization Project from the Agency for Healthcare Research and Quality was analyzed. A total of 87 039 711 children and adults (mean [SD] age, 57.7 [0.98] years for those with a primary diagnosis of pemphigus; 70.6 [0.32] years for those with a secondary diagnosis of pemphigus; and 47.9 [0.19] years for those without a diagnosis of pemphigus) were studied. Data analysis was performed from June 1 to August 30, 2015. MAIN OUTCOMES AND MEASURES: Hospitalization rates, length of stay, and cost of care.
RESULTS: There were 1185 and 5221 patients admitted with a primary or secondary diagnosis of pemphigus, respectively; when factoring in weights that generalize the sample to the entire hospitalized US cohort, these admissions represented weighted frequencies of 5647 and 24 880, respectively. In multivariable logistic regression models with stepwise selection, increasing age (adjusted odds ratios [95% CIs]: 18-39 years: 5.53 [4.28-7.14], P < .001; 40-59 years: 10.98 [8.46-14.24], P < .001; 60-79 years: 7.54 [5.75-9.89], P < .001; ≥80 years: 7.57 [5.71-10.04], P < .001), female sex (1.10 [1.01-1.20], P = .047), nonwhite race/ethnicity (black: 1.94 [1.75-2.14], P < .001; Hispanic: 4.10 [3.74-4.48], P < .001; Asian: 3.16 [2.68-3.73], P < .001; Native American: 2.11 [1.45-3.08], P < .001), lower household income (quartile 2: 1.19 [1.07-1.32], P < .001), being insured with Medicare (1.56 [1.41-1.74], P < .001) or Medicaid (1.55 [1.39-1.73], P < .001), number of chronic conditions (2-5: 2.36 [2.10-2.65], P < .001; ≥6: 1.47 [1.29-1.69], P < .001), hospital location in a metropolitan area (not metropolitan or micropolitan: 0.60 [0.49-0.72], P < .001), and summer season (1.12 [1.02-1.23], P = .02) were all associated with hospitalization for pemphigus. The total inflation-adjusted cost of care for patients with a primary inpatient diagnosis of pemphigus was $74 466 305, with a mean (SD) annual cost of $14 520.93 ($913.22). The inflation-adjusted cost of care for patients with a primary diagnosis of pemphigus increased significantly from 2002 to 2012 (analysis of variance, P < .001). In particular, length of stay was higher in racial/ethnic minorities compared with whites (survey linear regression, log β [95% CI]: black: 0.076 [0.075-0.076]; Hispanic: 0.021 [0.021-0.022]; Asian: 0.037 [0.036-0.039]; Native American: 0.010 [0.0076-0.013]), lower quartile household income (quartile 1: 0.024 [0.023-0.024]; quartile 2: 0.0029 [0.0022-0.0035]), and those without private insurance (Medicare: 0.12 [0.12-0.12]; Medicaid: 0.082 [0.081-0.083]; no charge: 0.051 [0.047-0.055]). CONCLUSIONS AND RELEVANCE: There is a significant inpatient burden for pemphigus in the United States. Moreover, there appear to be racial/ethnic and health care disparities with respect to pemphigus, such that poor, nonwhite, and/or uninsured or underinsured patients have higher odds of hospitalization.

Entities:  

Mesh:

Year:  2016        PMID: 26865293     DOI: 10.1001/jamadermatol.2015.5240

Source DB:  PubMed          Journal:  JAMA Dermatol        ISSN: 2168-6068            Impact factor:   10.282


  8 in total

Review 1.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

2.  Trends in emergency department visits due to sunburn and factors associated with severe sunburns in the United States.

Authors:  Raghav Tripathi; Rishabh S Mazmudar; Konrad D Knusel; Harib H Ezaldein; Jeremy S Bordeaux; Jeffrey F Scott
Journal:  Arch Dermatol Res       Date:  2020-04-09       Impact factor: 3.017

3.  Inpatient burden of juvenile dermatomyositis among children in the United States.

Authors:  Michael C Kwa; Jonathan I Silverberg; Kaveh Ardalan
Journal:  Pediatr Rheumatol Online J       Date:  2018-11-13       Impact factor: 3.054

4.  The Risk of Pulmonary Embolism in Patients With Pemphigus: A Population-Based Large-Scale Longitudinal Study.

Authors:  Khalaf Kridin; Mouhammad Kridin; Kyle T Amber; Guy Shalom; Doron Comaneshter; Erez Batat; Arnon D Cohen
Journal:  Front Immunol       Date:  2019-07-24       Impact factor: 7.561

Review 5.  Cost-of-illness studies in rare diseases: a scoping review.

Authors:  Lidia García-Pérez; Renata Linertová; Cristina Valcárcel-Nazco; Manuel Posada; Inigo Gorostiza; Pedro Serrano-Aguilar
Journal:  Orphanet J Rare Dis       Date:  2021-04-13       Impact factor: 4.123

Review 6.  Burden of pemphigus vulgaris with a particular focus on women: A review.

Authors:  Nika Kianfar; Shayan Dasdar; Hamidreza Mahmoudi; Maryam Daneshpazhooh
Journal:  Int J Womens Dermatol       Date:  2022-10-03

7.  Characteristics of hospitalized dermatomyositis patients with underlying malignancy: a nationally representative retrospective cohort study.

Authors:  Raghav Tripathi; Anthony P Fernandez
Journal:  Arch Dermatol Res       Date:  2020-08-17       Impact factor: 3.017

8.  Association between psoriasis, psoriatic arthritis and gastrointestinal disease : An exploratory nationwide inpatient sample analysis.

Authors:  Ahmed Yousaf; Rahul Raiker; Stephen M Davis; Swapna Gayam; Zachary Zinn
Journal:  Wien Klin Wochenschr       Date:  2020-09-23       Impact factor: 2.275

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.